Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: A prospective proof-of-concept cohort study

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Nikpour, Mandana ^a,b   Urowitz, Murray B ^a   Ibanez, Dominique ^a   Harvey, Paula J ^c   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY SCORE; DRUG USE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTIVE VALUE; PROOF OF CONCEPT; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; MIDDLE AGED; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; UPREGULATION;

ADULT; BLOOD PRESSURE; CHOLESTEROL; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 80053173790     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3473     Document Type: Article

References (20)

1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senécal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337
3. Vasan RS, D'Agostino RB Sr: Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005, 111:542-545
4. Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137-2143
5. Nikpour M, Gladman DD, Ibanez D, Harvey PJ, Urowitz MB: Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. Arthritis Res Ther 2010, 12: R125
6. Lee P, Urowitz MB, Bookman AA, Koehler BE, Smythe HA, Gordon DA, Ogryzlo MA: Systemic lupus erythematosus: a review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977, 46:1-32
7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277
8. Craig SR, Amin RV, Russell DW, Paradise NF: Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000, 15:395-399
9. Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291
10. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239
12. Gladman DD, Urowitz MB, Kagal A, Hallett D: Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000, 27:377-379
13. Ibanez D, Gladman DD, Urowitz MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005, 32:824-827
14. Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259
15. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM: Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008, 59:169-175
16. Sachet JC, Borba EF, Bonfa E, Vinagre CG, Silva VM, Maranhao RC: Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16:273-278
17. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA: Cholesterollowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322-326
18. Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD: Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009, 36:2454-2461
19. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28
20. Gladman DD, Urowitz MB: Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987, 14(Suppl 13):223-226